SG11201903889TA - Crenolanib for treating flt3 mutated proliferative disorders associated mutations - Google Patents

Crenolanib for treating flt3 mutated proliferative disorders associated mutations

Info

Publication number
SG11201903889TA
SG11201903889TA SG11201903889TA SG11201903889TA SG11201903889TA SG 11201903889T A SG11201903889T A SG 11201903889TA SG 11201903889T A SG11201903889T A SG 11201903889TA SG 11201903889T A SG11201903889T A SG 11201903889TA SG 11201903889T A SG11201903889T A SG 11201903889TA
Authority
SG
Singapore
Prior art keywords
international
crenolanib
dallas
patient
flt3
Prior art date
Application number
SG11201903889TA
Inventor
Vinay Jain
Original Assignee
Arog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62020370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201903889T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals Inc filed Critical Arog Pharmaceuticals Inc
Publication of SG11201903889TA publication Critical patent/SG11201903889TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

Title: CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS (57) : The present invention includes methods for treating a FLT3 mutat- ed proliferative disorder comprising: measuring expression of a mutated FLT3 and one or more genetic abnormalities in a sample obtained from a tumor sample ob- tained from the patient, wherein the presence of the one or more genetic abnormal- ities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, wherein the crenolanib increases a chance of survival of the patient having both the mutated FLT3 and the one or more genetic abnormalities, wherein the crenolanib, as shown below, is administered to a subject suffering from said disorder. W O 20 18/085 29 2 Al NH.. (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 May 2018 (11.05.2018) WIPO I PCT ill mu °million °nolo III m oimIE (10) International Publication Number WO 2018/085292 Al (51) International Patent Classification: A61K 31/4725 (2006.01) A61K 31/4184 (2006.01) A61K 31/4709 (2006.01) (21) International Application Number: PCT/US2017/059377 (22) International Filing Date: 31 October 2017 (31.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,475 02 November 2016 (02.11.2016) US 15/799,684 31 October 2017 (31.10.2017) US (71) Applicant: AROG PHARMACEUTICALS, INC. [US/US]; 5420 LBJ Freeway, Suite 410, Dallas, TX 75240 (US). (72) Inventor: JAIN, Vinay, K.; 10710 Inwood Road, Dallas, TX 75229 (US). (74) Agent: FLORES, Edwin, S. et al.; Chalker Flores, LLP, 14951 North Dallas Parkway, Suite 400, Dallas, TX 75254 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3))
SG11201903889TA 2016-11-02 2017-10-31 Crenolanib for treating flt3 mutated proliferative disorders associated mutations SG11201903889TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416475P 2016-11-02 2016-11-02
US15/799,684 US11078541B2 (en) 2016-11-02 2017-10-31 Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
PCT/US2017/059377 WO2018085292A1 (en) 2016-11-02 2017-10-31 Crenolanib for treating flt3 mutated proliferative disorders associated mutations

Publications (1)

Publication Number Publication Date
SG11201903889TA true SG11201903889TA (en) 2019-05-30

Family

ID=62020370

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903889TA SG11201903889TA (en) 2016-11-02 2017-10-31 Crenolanib for treating flt3 mutated proliferative disorders associated mutations

Country Status (19)

Country Link
US (2) US11078541B2 (en)
EP (1) EP3359155A4 (en)
JP (2) JP2019532011A (en)
KR (2) KR20200079351A (en)
CN (1) CN108778276A (en)
AU (1) AU2017353925A1 (en)
BR (1) BR112019008762A2 (en)
CA (1) CA3024012A1 (en)
CL (1) CL2019001208A1 (en)
CO (1) CO2019005466A2 (en)
EA (1) EA201991078A1 (en)
HK (1) HK1257195A1 (en)
IL (1) IL266303A (en)
MX (1) MX2019005008A (en)
PE (1) PE20191238A1 (en)
PH (1) PH12019500965A1 (en)
SG (1) SG11201903889TA (en)
WO (1) WO2018085292A1 (en)
ZA (1) ZA201903089B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085292A1 (en) * 2016-11-02 2018-05-11 Arog Pharmaceuticals, Inc. Crenolanib for treating flt3 mutated proliferative disorders associated mutations
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
EP3856173A4 (en) * 2018-09-26 2022-07-06 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CN109678849A (en) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 A kind of preparation method of anticancer drug
US11471451B2 (en) * 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN110531016B (en) * 2019-09-05 2021-08-31 合肥诺明药物安全研究有限公司 HYML-122 blood concentration quantitative analysis method
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN112921091B (en) * 2021-03-16 2022-01-21 南京先声医学检验实验室有限公司 Use of FLT3 gene mutation in predicting sensitivity of non-small cell lung cancer patient to immune checkpoint inhibitor therapy
JP2023063189A (en) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド Crenolanib for treating flt3 mutated proliferative disorders relapsing after or refractory to prior treatment
CN115141886B (en) * 2022-06-28 2023-06-06 厦门艾德生物医药科技股份有限公司 Probe primer set for detecting myelogenous leukemia gene mutation based on high-throughput sequencing and application thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc Novel angiogenesis inhibitors
UA75055C2 (en) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon
US6960590B2 (en) 2000-10-17 2005-11-01 Merck & Co. Inc. Orally active salts with tyrosine kinase activity
AR035885A1 (en) 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
IL161156A0 (en) 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AU2002360753B2 (en) 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
PE20040522A1 (en) 2002-05-29 2004-09-28 Novartis Ag DIARYLUREA DERIVATIVES DEPENDENT ON PROTEIN KINASE
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4741948B2 (en) 2002-08-14 2011-08-10 バーテックス ファーマシューティカルズ インコーポレイテッド Protein kinase inhibitors and their use
WO2004018419A2 (en) 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
PA8580301A1 (en) 2002-08-28 2005-05-24 Pfizer Prod Inc NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
JPWO2004039782A1 (en) 2002-10-29 2006-03-02 麒麟麦酒株式会社 Quinoline derivatives and quinazoline derivatives that inhibit Flt3 autophosphorylation and pharmaceutical compositions containing them
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
AR042052A1 (en) 2002-11-15 2005-06-08 Vertex Pharma USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
DK1641780T3 (en) 2003-06-24 2009-02-02 Pfizer Prod Inc Methods for Preparation of 1 - [(benzimidazol-1yl) quinolin-8-yl] -piperidin-4-ylamine derivatives
EP2417267B1 (en) * 2009-04-06 2016-08-17 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
AU2013232379A1 (en) * 2012-03-12 2014-09-25 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
TWI599356B (en) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 Method of inhibiting mutant c-kit
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanib for treatment of mutated flt3 proliferative disorders
WO2018085292A1 (en) * 2016-11-02 2018-05-11 Arog Pharmaceuticals, Inc. Crenolanib for treating flt3 mutated proliferative disorders associated mutations

Also Published As

Publication number Publication date
IL266303A (en) 2019-06-30
CN108778276A (en) 2018-11-09
US20210324481A1 (en) 2021-10-21
EA201991078A1 (en) 2019-11-29
KR20200079351A (en) 2020-07-02
KR20180074792A (en) 2018-07-03
JP2022071099A (en) 2022-05-13
AU2017353925A1 (en) 2018-09-27
EP3359155A4 (en) 2019-05-22
EP3359155A1 (en) 2018-08-15
MX2019005008A (en) 2019-09-10
PH12019500965A1 (en) 2019-12-02
CO2019005466A2 (en) 2019-07-31
PE20191238A1 (en) 2019-09-11
US11078541B2 (en) 2021-08-03
JP2019532011A (en) 2019-11-07
WO2018085292A1 (en) 2018-05-11
CL2019001208A1 (en) 2019-07-26
HK1257195A1 (en) 2019-10-18
ZA201903089B (en) 2019-12-18
CA3024012A1 (en) 2018-05-11
BR112019008762A2 (en) 2019-07-16
US20180117031A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
SG11201903889TA (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones